Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Paul A. Heidenreich, Pamela B. Morris, Khurram Nasir, Erin D. Michos, Vera A. Bittner, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

33 Scopus citations
Original languageEnglish (US)
Pages (from-to)2572-2574
Number of pages3
Issue number25
StatePublished - Jun 20 2017
Externally publishedYes


  • cardiovascular disease
  • cholesterol
  • lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this